Company / Accounts Receivable
IGC Pharma, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$34.0K
FY2025
5-year range
$34.0K / $175.0K
FY2021-FY2025
Trend
-12.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has declined for 4 consecutive years, from $175,000 in FY2021 to $34,000 in FY2025.
Based on SEC 10-K filings.
$34,000 in FY2025 with a 5-year CAGR of -23.9%.
Declined from $107,000 to $34,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -35.2%
- 5-Year CAGR
- -23.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- IGC Pharma, Inc.'s accounts receivable has declined for 4 consecutive years.
- 5-year CAGR of -23.9%, indicating a declining trend.
- In FY2025, accounts receivable decreased 12.8% year-over-year.
- Peak accounts receivable was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.0K | -12.8% |
| FY2024 | $39.0K | -63.6% |
| FY2023 | $107.0K | -14.4% |
| FY2022 | $125.0K | -28.6% |
| FY2021 | $175.0K | +31.6% |
| FY2020 | $133.0K | +58.3% |
| FY2019 | $84.0K | -84.9% |
| FY2018 | $557.8K | -25.9% |
| FY2017 | $752.9K | -21.8% |
| FY2016 | $962.7K | -3.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026